JP2013521296A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013521296A5 JP2013521296A5 JP2012556165A JP2012556165A JP2013521296A5 JP 2013521296 A5 JP2013521296 A5 JP 2013521296A5 JP 2012556165 A JP2012556165 A JP 2012556165A JP 2012556165 A JP2012556165 A JP 2012556165A JP 2013521296 A5 JP2013521296 A5 JP 2013521296A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- amount
- fragment
- antibody
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 36
- 238000009472 formulation Methods 0.000 claims 31
- 239000012634 fragment Substances 0.000 claims 25
- 235000002639 sodium chloride Nutrition 0.000 claims 21
- 150000003839 salts Chemical class 0.000 claims 17
- 239000004094 surface-active agent Substances 0.000 claims 12
- 235000018102 proteins Nutrition 0.000 claims 11
- 102000004169 proteins and genes Human genes 0.000 claims 11
- 108090000623 proteins and genes Proteins 0.000 claims 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 9
- 239000007951 isotonicity adjuster Substances 0.000 claims 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 8
- 239000000872 buffer Substances 0.000 claims 8
- 229920001983 poloxamer Polymers 0.000 claims 7
- 239000003381 stabilizer Substances 0.000 claims 7
- 230000003204 osmotic effect Effects 0.000 claims 6
- 229920000136 polysorbate Polymers 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 235000014304 histidine Nutrition 0.000 claims 5
- 238000002360 preparation method Methods 0.000 claims 5
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 claims 4
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims 4
- 239000004471 Glycine Substances 0.000 claims 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 239000011780 sodium chloride Substances 0.000 claims 4
- 239000000176 sodium gluconate Substances 0.000 claims 4
- 235000012207 sodium gluconate Nutrition 0.000 claims 4
- 229940005574 sodium gluconate Drugs 0.000 claims 4
- 239000001540 sodium lactate Substances 0.000 claims 4
- 235000011088 sodium lactate Nutrition 0.000 claims 4
- 229940005581 sodium lactate Drugs 0.000 claims 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 3
- 102000004190 Enzymes Human genes 0.000 claims 3
- 108090000790 Enzymes Proteins 0.000 claims 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 3
- 229930195725 Mannitol Natural products 0.000 claims 3
- 229920001213 Polysorbate 20 Polymers 0.000 claims 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 3
- 229930006000 Sucrose Natural products 0.000 claims 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 239000000594 mannitol Substances 0.000 claims 3
- 235000010355 mannitol Nutrition 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 229950008882 polysorbate Drugs 0.000 claims 3
- 229940068977 polysorbate 20 Drugs 0.000 claims 3
- 229920000053 polysorbate 80 Polymers 0.000 claims 3
- 229940068968 polysorbate 80 Drugs 0.000 claims 3
- 229960002668 sodium chloride Drugs 0.000 claims 3
- 239000000600 sorbitol Substances 0.000 claims 3
- 239000005720 sucrose Substances 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical group [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 2
- 229940024606 amino acid Drugs 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims 2
- 239000006172 buffering agent Substances 0.000 claims 2
- 150000002016 disaccharides Chemical class 0.000 claims 2
- 239000008101 lactose Substances 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 150000002772 monosaccharides Chemical class 0.000 claims 2
- 229960000502 poloxamer Drugs 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 150000005846 sugar alcohols Chemical group 0.000 claims 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims 2
- HMFKFHLTUCJZJO-UHFFFAOYSA-N 2-{2-[3,4-bis(2-hydroxyethoxy)oxolan-2-yl]-2-(2-hydroxyethoxy)ethoxy}ethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOCC(OCCO)C1OCC(OCCO)C1OCCO HMFKFHLTUCJZJO-UHFFFAOYSA-N 0.000 claims 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 229920001219 Polysorbate 40 Polymers 0.000 claims 1
- 229920001214 Polysorbate 60 Polymers 0.000 claims 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 235000019270 ammonium chloride Nutrition 0.000 claims 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims 1
- 235000011130 ammonium sulphate Nutrition 0.000 claims 1
- SOIFLUNRINLCBN-UHFFFAOYSA-N ammonium thiocyanate Chemical compound [NH4+].[S-]C#N SOIFLUNRINLCBN-UHFFFAOYSA-N 0.000 claims 1
- 229960003589 arginine hydrochloride Drugs 0.000 claims 1
- 239000003114 blood coagulation factor Substances 0.000 claims 1
- 229940019700 blood coagulation factors Drugs 0.000 claims 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims 1
- 239000001110 calcium chloride Substances 0.000 claims 1
- 229910001628 calcium chloride Inorganic materials 0.000 claims 1
- 235000011148 calcium chloride Nutrition 0.000 claims 1
- 239000003599 detergent Substances 0.000 claims 1
- 150000002333 glycines Chemical class 0.000 claims 1
- 150000002411 histidines Chemical class 0.000 claims 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 1
- 229910001629 magnesium chloride Inorganic materials 0.000 claims 1
- 235000011147 magnesium chloride Nutrition 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- 239000011976 maleic acid Substances 0.000 claims 1
- 150000007522 mineralic acids Chemical class 0.000 claims 1
- 150000007524 organic acids Chemical class 0.000 claims 1
- 235000005985 organic acids Nutrition 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 claims 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 claims 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims 1
- 229940101027 polysorbate 40 Drugs 0.000 claims 1
- 229940113124 polysorbate 60 Drugs 0.000 claims 1
- 229940071643 prefilled syringe Drugs 0.000 claims 1
- 239000001632 sodium acetate Substances 0.000 claims 1
- 235000017281 sodium acetate Nutrition 0.000 claims 1
- VGTPCRGMBIAPIM-UHFFFAOYSA-M sodium thiocyanate Chemical compound [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- 239000011592 zinc chloride Substances 0.000 claims 1
- 235000005074 zinc chloride Nutrition 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33919110P | 2010-03-01 | 2010-03-01 | |
| US61/339,191 | 2010-03-01 | ||
| PCT/US2011/026647 WO2011109365A2 (en) | 2010-03-01 | 2011-03-01 | Concentrated protein formulations and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016095589A Division JP6229007B2 (ja) | 2010-03-01 | 2016-05-11 | 濃縮されたタンパク質製剤およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013521296A JP2013521296A (ja) | 2013-06-10 |
| JP2013521296A5 true JP2013521296A5 (enExample) | 2014-04-17 |
| JP5937523B2 JP5937523B2 (ja) | 2016-06-22 |
Family
ID=44542798
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012556165A Active JP5937523B2 (ja) | 2010-03-01 | 2011-03-01 | 濃縮されたタンパク質製剤およびその使用 |
| JP2016095589A Active JP6229007B2 (ja) | 2010-03-01 | 2016-05-11 | 濃縮されたタンパク質製剤およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016095589A Active JP6229007B2 (ja) | 2010-03-01 | 2016-05-11 | 濃縮されたタンパク質製剤およびその使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9956165B2 (enExample) |
| EP (1) | EP2542221A4 (enExample) |
| JP (2) | JP5937523B2 (enExample) |
| KR (1) | KR101853981B1 (enExample) |
| CN (2) | CN105521491B (enExample) |
| AU (2) | AU2011223805B2 (enExample) |
| BR (1) | BR112012022223B1 (enExample) |
| CA (1) | CA2794929C (enExample) |
| IL (1) | IL221748B (enExample) |
| MX (1) | MX347504B (enExample) |
| NZ (1) | NZ602685A (enExample) |
| RU (1) | RU2626512C2 (enExample) |
| SG (1) | SG184355A1 (enExample) |
| WO (1) | WO2011109365A2 (enExample) |
| ZA (1) | ZA201207331B (enExample) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012022223B1 (pt) * | 2010-03-01 | 2022-08-09 | Cytodyn Inc | Formulação de proteína concentrada, uso e método de preparação da mesma |
| SG190006A1 (en) | 2010-11-04 | 2013-06-28 | Boehringer Ingelheim Int | Anti-il-23 antibodies |
| CN104023748B (zh) * | 2011-10-28 | 2018-03-02 | 诚信生物公司 | 含有氨基酸的蛋白质制剂 |
| JP6345123B2 (ja) * | 2012-02-16 | 2018-06-20 | サンタラス， インコーポレイテッド | 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物 |
| NZ700802A (en) | 2012-05-03 | 2017-06-30 | Boehringer Ingelheim Int | Anti-il-23p19 antibodies |
| AU2013312300A1 (en) | 2012-09-07 | 2015-04-16 | Coherus Biosciences, Inc. | Stable aqueous formulations of adalimumab |
| KR20210021153A (ko) * | 2012-09-20 | 2021-02-24 | 모르포시스 아게 | 류마티스 관절염에 대한 치료 |
| HK1208231A1 (en) * | 2012-09-20 | 2016-02-26 | Morphosys Ag | Treatment for rheumatoid arthritis |
| IL312865B2 (en) | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| ES2607489T3 (es) | 2014-05-23 | 2017-03-31 | Ares Trading S.A. | Composición farmacéutica líquida |
| HUE029849T2 (en) | 2014-05-23 | 2017-04-28 | Ares Trading Sa | Liquid pharmaceutical composition |
| EP2946766B1 (en) | 2014-05-23 | 2016-03-02 | Ares Trading S.A. | Liquid pharmaceutical composition |
| US11357857B2 (en) | 2014-06-20 | 2022-06-14 | Comera Life Sciences, Inc. | Excipient compounds for protein processing |
| US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
| US20160074515A1 (en) | 2014-06-20 | 2016-03-17 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
| EP3708679A1 (en) | 2014-07-24 | 2020-09-16 | Boehringer Ingelheim International GmbH | Biomarkers useful in the treatment of il-23a related diseases |
| BR112017003252A2 (pt) | 2014-08-20 | 2017-11-28 | Cytodyn Inc | terapia com anticorpos contra hiv como substituto de tratamento |
| MY192824A (en) | 2014-09-03 | 2022-09-12 | Boehringer Ingelheim Int | Compound targeting il-23a and tnf-alpha and uses thereof |
| JP6716577B2 (ja) | 2014-10-01 | 2020-07-01 | イーグル・バイオロジクス・インコーポレイテッドＥａｇｌｅ Ｂｉｏｌｏｇｉｃｓ， Ｉｎｃ． | 粘度低下物質を含有する、多糖および核酸の調合薬 |
| BR112017007393A2 (pt) * | 2014-10-18 | 2017-12-19 | Pfizer | composições de anticorpo anti-il-7r |
| WO2016080367A1 (ja) | 2014-11-18 | 2016-05-26 | 塩野義製薬株式会社 | 安定化されたペプチド組成物 |
| JP6802791B2 (ja) | 2014-12-04 | 2020-12-23 | ヤンセン バイオテツク，インコーポレーテツド | 急性骨髄性白血病の治療のための抗ｃｄ３８抗体 |
| KR101776879B1 (ko) | 2015-01-19 | 2017-09-08 | 주식회사 녹십자 | 항-egfr 항체를 포함하는 약학 제제 |
| EP3250596A1 (en) | 2015-01-28 | 2017-12-06 | Pfizer Inc | Stable aqueous anti- vascular endothelial growth factor (vegf) antibody formulation |
| IL321788A (en) | 2015-02-04 | 2025-08-01 | Boehringer Ingelheim Int | Methods of treating inflammatory diseases |
| EP3053572A1 (en) * | 2015-02-06 | 2016-08-10 | Ares Trading S.A. | Liquid pharmaceutical composition |
| SG11201705484WA (en) * | 2015-02-09 | 2017-08-30 | Ucb Biopharma Sprl | Pharmaceutical formulation |
| EP3081942A1 (en) * | 2015-04-17 | 2016-10-19 | Roche Diagniostics GmbH | Pressure transmission liquid for cellular analyzer, cellular analyzer and method for analyzing a liquid cellular sample |
| BR112017024877A2 (pt) | 2015-05-20 | 2019-09-17 | Janssen Biotech, Inc. | anticorpo anti-cd38 e seu uso no tratamento de amiloidose de cadeia leve e outras malignidades hematológicas positivas para cd38 |
| CN107847514A (zh) * | 2015-06-23 | 2018-03-27 | 西托戴恩股份有限公司 | 炎症、癌症、自身免疫和其它病症中ccl5配体结合ccr5受体的抑制作用和ccr5/ccl5轴信号传导的改变 |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| WO2017057644A1 (ja) * | 2015-09-30 | 2017-04-06 | 持田製薬株式会社 | 高濃度抗体含有液体製剤 |
| US11229702B1 (en) | 2015-10-28 | 2022-01-25 | Coherus Biosciences, Inc. | High concentration formulations of adalimumab |
| MD3827845T2 (ro) | 2015-11-03 | 2022-09-30 | Janssen Biotech Inc | Formulări subcutanate de anticorpi anti-CD38 și utilizări ale acestora |
| SG11201807402PA (en) | 2016-03-31 | 2018-09-27 | Vhsquared Ltd | Compositions |
| US11071782B2 (en) | 2016-04-20 | 2021-07-27 | Coherus Biosciences, Inc. | Method of filling a container with no headspace |
| TWI826351B (zh) * | 2016-05-31 | 2023-12-21 | 大陸商鴻運華寧（杭州）生物醫藥有限公司 | Ｒ抗體,其藥物組合物及其應用 |
| US20190233533A1 (en) | 2016-06-28 | 2019-08-01 | Umc Utrecht Holding B.V. | Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38 |
| EP3493832A1 (en) | 2016-08-05 | 2019-06-12 | CSL Behring GmbH | Pharmaceutical formulations of c1 esterase inhibitor |
| CN110366429B (zh) * | 2017-03-01 | 2024-10-11 | 免疫医疗有限公司 | 单克隆抗体的配制品 |
| CN110769848A (zh) * | 2017-05-16 | 2020-02-07 | 瑞士奥克特珐玛公司 | C1-酯酶抑制剂制剂 |
| WO2019028340A1 (en) * | 2017-08-03 | 2019-02-07 | Jazz Pharmaceuticals Ireland Limited | FORMULATIONS COMPRISING A HIGH CONCENTRATION NUCLEIC ACID |
| KR102208378B1 (ko) * | 2017-08-17 | 2021-01-28 | 주식회사 녹십자 | 항-egfr 항체를 포함하는 약학 제제 |
| WO2019055995A1 (en) | 2017-09-18 | 2019-03-21 | Cytodyn Inc. | SCREENING METHODS FOR IDENTIFYING AND TREATING SUB-POPULATIONS OF HIV-1 INFECTED PATIENTS SUITABLE FOR LONG-TERM THERAPY WITH AN ANTI-CCR5 AGENT |
| MA50514A (fr) | 2017-10-31 | 2020-09-09 | Janssen Biotech Inc | Méthodes de traitement du myélome multiple à haut risque |
| GB201719447D0 (en) | 2017-11-23 | 2018-01-10 | Ucb Biopharma Sprl | Pharmaceutical composition |
| SG11202010684YA (en) | 2018-05-10 | 2020-11-27 | Regeneron Pharma | High concentration vegf receptor fusion protein containing formulations |
| SG11202108627SA (en) | 2019-02-18 | 2021-09-29 | Lilly Co Eli | Therapeutic antibody formulation |
| KR20210137520A (ko) | 2019-03-08 | 2021-11-17 | 베링거 인겔하임 인터내셔날 게엠베하 | 항-il-36r 항체 제형 |
| CN114286690A (zh) * | 2019-04-23 | 2022-04-05 | 赛诺菲 | 稳定的低粘度抗体配制品及其用途 |
| TW202535466A (zh) | 2019-09-09 | 2025-09-16 | 德商百靈佳殷格翰國際股份有限公司 | 抗-il-23p19抗體調配物 |
| US11045546B1 (en) | 2020-03-30 | 2021-06-29 | Cytodyn Inc. | Methods of treating coronavirus infection |
| US20230235037A1 (en) * | 2020-04-22 | 2023-07-27 | Chemomab Ltd. | Method of treatment using anti-ccl24 antibody |
| CN115996748A (zh) * | 2020-05-29 | 2023-04-21 | 奇努克医疗公司 | 用APRIL结合抗体治疗IgA肾病的方法 |
| CN111595658B (zh) * | 2020-06-06 | 2023-11-14 | 宾傲 | 一种提取细胞中蛋白的裂解液及其制备方法 |
| CN116034985B (zh) * | 2022-12-12 | 2025-09-16 | 武汉呵尔医疗科技发展有限公司 | 一种细胞保护液、hpv e6/e7质控片的制备方法及应用 |
| WO2025089468A1 (ko) * | 2023-10-27 | 2025-05-01 | 주식회사 엔솔바이오사이언스 | 펩타이드 함유 액상제제 및 그 제조방법 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1516628E (pt) | 1995-07-27 | 2013-09-24 | Genentech Inc | Formulação de proteína liofilizada isotónica estável |
| PT1324776E (pt) | 2000-10-12 | 2009-12-23 | Genentech Inc | Formulações de proteína concentradas de viscosidade reduzida |
| IL161677A0 (en) * | 2001-11-08 | 2004-09-27 | Protein Design Labs | Stable liquid pharmaceutical formulation of igg antibodies |
| ES2325653T3 (es) * | 2001-12-21 | 2009-09-11 | Novo Nordisk Health Care Ag | Composicion liquida de polipeptidos del factor vii. |
| WO2003068260A1 (fr) | 2002-02-14 | 2003-08-21 | Chugai Seiyaku Kabushiki Kaisha | Produits pharmaceutiques en solution contenant des anticorps |
| US7122185B2 (en) | 2002-02-22 | 2006-10-17 | Progenics Pharmaceuticals, Inc. | Anti-CCR5 antibody |
| EP1478738B1 (en) | 2002-02-22 | 2008-11-12 | Progenics Pharmaceuticals, Inc. | Anti-ccr5 antibody |
| PL215168B1 (pl) * | 2002-02-27 | 2013-10-31 | Immunex Corp | Formulacja polipeptydowa |
| CA2517310C (en) | 2003-02-28 | 2015-11-24 | Chugai Seiyaku Kabushiki Kaisha | Stabilized protein-containing formulations comprising a poloxamer |
| HRP20050934B1 (hr) * | 2003-04-04 | 2014-09-26 | Genentech, Inc. | Formulacije s visokom koncentracijom antitijela i proteina |
| WO2005112893A1 (en) | 2004-05-12 | 2005-12-01 | Baxter International Inc. | Microspheres comprising protein and showing injectability at high concentrations of said agent |
| EP1750751B1 (en) * | 2004-06-01 | 2013-04-10 | Ares Trading S.A. | Stabilized interferon liquid formulations |
| US20070213270A1 (en) | 2004-06-16 | 2007-09-13 | Costantino Henry R | Peptide yy formulations having increased stability and resistance to microbial agents |
| EA014025B1 (ru) * | 2005-09-12 | 2010-08-30 | Новиммун С.А. | Композиции антитела против cd3 |
| UA97234C2 (ru) * | 2005-11-01 | 2012-01-25 | Уайєт | Раствор хлорида натрия для восстановления влагосодержания композиции лиофилизированного фактора ix |
| CN101378782A (zh) * | 2005-12-21 | 2009-03-04 | 惠氏公司 | 粘度降低的蛋白质制剂及其用途 |
| CA2666492C (en) * | 2006-10-20 | 2012-07-17 | Douglas Rehder | Stable polypeptide formulations |
| BR112012022223B1 (pt) * | 2010-03-01 | 2022-08-09 | Cytodyn Inc | Formulação de proteína concentrada, uso e método de preparação da mesma |
-
2011
- 2011-03-01 BR BR112012022223-6A patent/BR112012022223B1/pt active IP Right Grant
- 2011-03-01 EP EP11751179.0A patent/EP2542221A4/en active Pending
- 2011-03-01 US US13/582,243 patent/US9956165B2/en active Active
- 2011-03-01 CN CN201510815109.5A patent/CN105521491B/zh active Active
- 2011-03-01 AU AU2011223805A patent/AU2011223805B2/en active Active
- 2011-03-01 SG SG2012072542A patent/SG184355A1/en unknown
- 2011-03-01 NZ NZ602685A patent/NZ602685A/en unknown
- 2011-03-01 CA CA2794929A patent/CA2794929C/en active Active
- 2011-03-01 RU RU2012141655A patent/RU2626512C2/ru active
- 2011-03-01 MX MX2012010114A patent/MX347504B/es active IP Right Grant
- 2011-03-01 JP JP2012556165A patent/JP5937523B2/ja active Active
- 2011-03-01 KR KR1020127025849A patent/KR101853981B1/ko not_active Expired - Fee Related
- 2011-03-01 WO PCT/US2011/026647 patent/WO2011109365A2/en not_active Ceased
- 2011-03-01 CN CN201180019594.5A patent/CN102946861B/zh active Active
-
2012
- 2012-09-02 IL IL221748A patent/IL221748B/en active IP Right Grant
- 2012-10-01 ZA ZA2012/07331A patent/ZA201207331B/en unknown
-
2016
- 2016-01-28 AU AU2016200495A patent/AU2016200495B2/en active Active
- 2016-05-11 JP JP2016095589A patent/JP6229007B2/ja active Active
-
2018
- 2018-03-19 US US15/925,255 patent/US11571383B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013521296A5 (enExample) | ||
| CA2794929A1 (en) | Concentrated protein formulations and uses thereof | |
| CN104623656B (zh) | 依那西普的稳定液体制剂 | |
| ES2742868T3 (es) | Formulaciones de anticuerpos anti-receptor de prolactina | |
| FI3506886T3 (fi) | Erittäin väkevöityjä alhaisen viskositeetin masp-2:ta estäviä vasta-aineformulaatioita, tarvikesarjoja ja menetelmiä | |
| AU2017334290B2 (en) | Novel formulations | |
| ES2925232T3 (es) | Proceso para la formulación farmacéutica liofilizada de una proteína terapéutica | |
| HRP20191923T1 (hr) | Postupci i sastavi za isporuku arilsulfataze a u cns | |
| JP2013515071A5 (enExample) | ||
| RU2020112952A (ru) | Жидкая фармацевтическая композиция | |
| HRP20240635T1 (hr) | Dugodjelujući hormoni rasta i postupci proizvodnje istog | |
| JP2019509311A5 (enExample) | ||
| FI3209681T3 (fi) | Peptidivariantteja käsittäviä farmaseuttisia koostumuksia ja niiden käyttömenetelmiä | |
| JP2019536761A5 (enExample) | ||
| RU2015119603A (ru) | Стабильная фармацевтическая композиция на основе слитого белка tnfr:fc | |
| JP2022097600A (ja) | 抗ＴＮＦα抗体の液状製剤 | |
| JPWO2015190378A1 (ja) | 安定なアダリムマブ水性製剤 | |
| JP2015535237A5 (enExample) | ||
| JP2016519670A5 (enExample) | ||
| US20260069688A1 (en) | Stable antibody composition | |
| IL277721B2 (en) | Medical infusion pump system for the delivery of an insulin compound | |
| RU2016119565A (ru) | Полипептиды длительного действия и способы их получения и введения | |
| CN115666643A (zh) | 用于治疗异位性皮肤炎的抗il-36r抗体 | |
| EA043419B1 (ru) | Способ получения лиофилизированного фармацевтического состава на основе терапевтического белка | |
| JP2024522165A (ja) | ２０１９新型コロナウイルス抗体含有医薬製剤 |